EU/3/14/1308: Orphan designation for the treatment of autosomal dominant polycystic liver disease
sodium ascorbate / menadione sodium bisulfite
Table of contents
On 22 August 2014, orphan designation (EU/3/14/1308) was granted by the European Commission to JJGConsultancy Ltd, United Kingdom, for sodium ascorbate and menadione sodium bisulfite for the treatment of autosomal dominant polycystic liver disease.
The sponsorship was transferred to MCA Regulatory Limited, United Kingdom, in June 2016.
Treatment of autosomal dominant polycystic liver disease
|Orphan designation status||
|EU designation number||
|Date of designation||
MCA Regulatory Limited
195 Silver Street
Essex CM24 78HB
Tel. +44 (0)1279 816 487
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: